Menu

ADD conference

Dr. Goodman, panelist, 2020 Annual APSARD conference January 12, Washington DC

, , ,

Dr. David W. Goodman has been invited as a panelist to discuss clinical implications of adult ADHD research and the use of medications in complex treatment. APSARD, American Professional Society for ADHD and Related Disorders, is a nationally and internationally represented professional organization devoted to the advancement of ADHD education, research, and treatment. I have been a member of the Board of Directors for several years and now Co-chair for the Education Committee along with Dr. Len Adler at New York University.

I am honored to be invited this year as a panelist to discuss the clinical implications and translation of research to the care of patients. The title of the presentation “Plenary Session: Comparative Efficacy and Tolerability of ADHD Medications in Children/Adolescents and Adults: What is the Evidence and What Are the Implications for Guidelines, Algorithm Development, and Clinical Care“

The conference is open to all physicians and mental health professionals. Because of the scientific nature of the presentations, it is not open to the general public. The general public can take advantage of APSARD’s information by visiting www.adhdinadults.com for up to date and medically supported perspectives on diagnosis and treatment of ADHD in adults.

The APSARD conference this year will include representatives from the FDA to explore and understand the research review protocol to advance approval of proven effective medications.

Needless to say, in addition to caring for patients in my full time practice, I countinue to be actively involved with teaching/lecturing at continuing medical education conferences. Among other dates, I will be presenting at the Neuroscience Education Institute in Las Vegas in April 2020.

I advise my patients and their families to stay apprised of the current research and state of the art in diagnosis and effective treatments for ADHD. Don’t be fooled by marketing over research. Marketers will say “Let’s use it while it still works” meaning, once research investigates it, it may be nothing more than placebo. This couldn’t be more true then in the nutriceutical supplements for ADHD and memory. But that’s a discussion for another time.

Thank you for your time.

David W. Goodman, M.D., LFAPA

Dr. David W. Goodman interviewed by Vox.com Misdiagnosis of ADHD

, , , , , , , , , , , , ,

Dr. David W. Goodman was video interviewed by Vox.com on misdiagnosis of ADHD as a counterpoint to Dr. Allen Francis, psychiatrist, who believes ADHD is overdiagnosed. The video is excellently edited and very engaging. While it is easy to say ADHD is overdiagnosed because of the extensive media coverage, it is not overdiagnosis. The basis for my opinion lies in the research facts: 4.5% of US adults ages 18-44 are believed to have ADHD, a diagnosis whose basis is the persistence of symptoms since childhood of which 75% were never diagnosed as children. Of the adults with ADHD in the U.S., only 25% have been treated in the last year. With the prevalence rate of ADHD internationally ranges from approximately 2-10%, appallingly few adults outside of the U.S. are identified and treated.

Setting aside those adults who are accurately diagnosed  with a comprehensive evaluation, there are patients who are given the diagnosis of ADHD and don’t have it. Inadequate clinician training, little time spent obtaining the history, and strong patient demand for ADHD can lead to misdiagnosis. These patients who do not have ADHD should not be placed on stimulant medication. More often, primary care clinicians are prescribing short-acting stimulants which can be abused, misused, and sold/given away to friends/customers.

SOME FACTS:

65% of all stimulants prescribed in the U.S. are prescribed primary care clinicians; 55% of all stimulants prescribed are short-acting; four international guidelines for the diagnosis and treatment of ADHD recommend long-acting stimulants as first line medication, not short-acting.

Well, that’s enough science for today. I provide this information so that if you are in a conversation about this topic, you are armed with meaningful data, beyond opinion.

As I have said before in my blogs, let science be the designated driver on the highway of opinions.

Faculty speaker, annual American Professional Society for ADHD and Related Disorders conference

, , , , , , , , , , , ,

American Professional Society for ADHD and Related Disorders (APSARD) is an organization founded by a national and international group of experts in ADHD treatment and research. The annual meeting, “ADHD Advances: Challenges and Opportunities” being held September 27 – 28, 2013 at the Hyatt Regency Washington on Capitol Hill in Washington, DC  brings together these experts and other professionals interested in learning and advancing their skills. The presentations are the cutting edge research, treatment options, and technology developments to further our understanding of ADHD and the co-existing psychiatric and medical disorders.  Information and discussions extend beyond U.S. research to include Canadian, European and Middle East research and treatments.

I am honored to be invited to present a 60 minute workshop on the “Choice and Optimal Dosing of Medications for Adults with ADHD” with my co-presenter Dr. Janet Standard, a psychiatric Advanced Practice Nurse at the NYU Health Services. 

The conference is open to professionals in the health care field and registration is available now. . this link, you can browse the conference agenda, location, and hotel accommodations. This is a top-level, relatively small conference that allows all participants to engage and exchange thoughts and ideas. If you are in the field of ADHD, this is a conference not to miss. See you there.

David W. Goodman, M.D.